![VICTOZA (liraglutide [rDNA origin]) 6mg/mL solution for SC injection by Novo Nordisk](http://media.empr.com/images/2013/03/01/victoza_350193_350194.jpg "VICTOZA (liraglutide [rDNA origin]) 6mg/mL solution for SC injection by Novo Nordisk")
Generic Name and Formulations:
Liraglutide [rDNA origin] 6mg/mL; soln for SC inj.
Company:
Novo Nordisk
| 05/06/13 |
| History of pancreatitis: consider other antidiabetic therapies. |
As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.
Give by SC inj in abdomen, thigh, or upper arm once daily. Initially 0.6mg/day for 1 week, then 1.2mg/day; may increase to 1.8mg/day. If >3 days elapsed since last dose, reinitiate at 0.6mg/day, then titrate. Renal impairment: caution with initiating or escalating doses.
<18yrs: not recommended.
Glucagon-like peptide-1 [GLP-1] receptor agonist.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Inform patients of thyroid cancer risk and symptoms. Not for treating type 1 diabetes or ketoacidosis. Not a substitute for insulin. Not recommended for first-line treatment in patients inadequately controlled on diet and exercise. Discontinue if pancreatitis is suspected; do not restart if confirmed. History of pancreatitis: consider other antidiabetic therapies. Renal or hepatic dysfunction. Gastroparesis. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant insulin (insufficient data); administer as separate injections not adjacent to each other. Hypoglycemia with sulfonylureas or insulin (consider reducing their doses). May affect absorption of other drugs (delayed gastric emptying). Monitor digoxin.
Headache, GI upset, antibody formation, immunogenicity reactions (eg, urticaria), constipation; rare: pancreatitis (discontinue if occurs), papillary thyroid carcinoma, anaphylactic reactions and angioedema (discontinue if occurs).
Multi-dose, prefilled pen (3mL)—2, 3